SCYNEXIS Reports Zero Revenue and $0.71 Loss Per Share in Q3 2026
SCYNEXIS reported no license agreement revenue in the quarter, compared with $334,000 a year earlier, while its net loss narrowed slightly. Lower R&D costs tied to the terminated MARIO Phase 3 study and higher interest and other income, including an R&D tax credit, contributed to the change.
Story updates
01:21:14 PM UTC
SquawkNews
Completed Phase 1 study of SCY-770, a first-in-class, highly selective, oral direct AMPK activator f
01:23:50 PM UTC
SquawkNews
Nov 05 (Reuters) - Scynexis Inc Q3 net income USD -8.458 million.
SCYNEXIS reported no license agreement revenue in 3Q 2026, compared with $334K a year earlier, while net loss narrowed slightly. Lower research and development costs associated with the terminated MARIO Phase 3 study and higher interest and other income, including research and development tax credi…